<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012437</article-id><article-id pub-id-type="publisher-id">ACM-39123</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_83479824.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血液灌流联合血液透析改善尿毒症患者皮肤瘙痒的临床机制研究
  Study on the Clinical Mechanism of Hemoperfusion Combined with Hemodialysis to Improve Skin Itching in Patients with Uremia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>解</surname><given-names>秀荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>季</surname><given-names>文萱</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>安</surname><given-names>茜</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>单</surname><given-names>文红</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>芬芬</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>俊彦</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff3"><addr-line>青岛大学第二临床医学院肾内科，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>2890</fpage><lpage>2897</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨血液灌流(hemoperfusion, HP)联合血液透析(hemodialysis, HD)对维持性血液透析(maintenance hemodialysis, MHD)患者皮肤瘙痒的改善情况及对患者血清白介素-31 (Interleukin-31, IL-31)、神经营养素-4 (neurotrophin-4, NT-4)及脑源性神经营养因子(brain derived neurotrophic factor, BDNF)水平的影响。方法：选取2019年7月~2020年6月于青岛市中心医院行维持性血液透析且患有皮肤瘙痒的患者64例，分为HD组和HP + HD组，对比两组患者治疗前后皮肤瘙痒情况、血生化指标、IL-31、NT-4、BDNF水平的变化情况。结果：两组患者治疗后皮肤瘙痒情况、β2-微球蛋白(β2-MG)、超敏-C反应蛋白(hs-CRP)、甲状旁腺激素(iPTH)及IL-31、NT-4水平均较治疗前减低，且HP + HD组患者改善情况优于HD组(P &lt; 0.05)。两组治疗后BDNF水平均较治疗前增加，但差异无统计学意义(P &gt; 0.05)。结论：HP + HD治疗可通过减少部分瘙痒相关因子，从而缓解患者的皮肤瘙痒情况，且效果明显优于单纯HD治疗。
    Objective: To explore the effect of hemoperfusion (HP) combined with hemodialysis (HD) on the improvement of skin itching and the levels of serum interleukin-31 (IL-31), neurotrophin-4 (NT-4) and brain-derived neurotrophic factor (BDNF) in maintenance hemodialysis (MHD) patients. Methods: 64 patients who underwent maintenance hemodialysis in Qingdao Central Hospital from July 2019 to June 2020 and suffered from skin pruritus were divided into HD group and HP + HD group. The changes of skin pruritus, blood biochemical indexes and the levels of IL-31, NT-4 and BDNF before and after treatment were compared between the two groups. Results: The skin pruritus, β2-microglobulin (β2-MG), hypersensitive C-reactive protein (hs-CRP) and parathyroid hormone (iPTH), IL-31, NT-4 in the two groups after treatment were lower than before treatment. The improvement of HP + HD group was better than that of HD group (P &lt; 0.05). The levels of BDNF after treatment increased compared with before treatment in two groups, but the difference before and after was not statistically significant (P &gt; 0.05). Conclusion: The treatment of HP + HD can relieve patients’ skin pruritus by reducing some itch-related factors, and the effect is significantly better than that of HD. 
   
   
    
  
 
</p></abstract><kwd-group><kwd>尿毒症，皮肤瘙痒，血液灌流，血液透析，IL-31，NT-4，BDNF, Uremia</kwd><kwd> Skin Itching</kwd><kwd> Hemoperfusion</kwd><kwd> Hemodialysis</kwd><kwd> IL-31</kwd><kwd> NT-4</kwd><kwd> BDNF</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨血液灌流(hemoperfusion, HP)联合血液透析(hemodialysis, HD)对维持性血液透析(maintenance hemodialysis, MHD)患者皮肤瘙痒的改善情况及对患者血清白介素-31 (Interleukin-31, IL-31)、神经营养素-4 (neurotrophin-4, NT-4)及脑源性神经营养因子(brain derived neurotrophic factor, BDNF)水平的影响。方法：选取2019年7月~2020年6月于青岛市中心医院行维持性血液透析且患有皮肤瘙痒的患者64例，分为HD组和HP + HD组，对比两组患者治疗前后皮肤瘙痒情况、血生化指标、IL-31、NT-4、BDNF水平的变化情况。结果：两组患者治疗后皮肤瘙痒情况、b2-微球蛋白(b2-MG)、超敏-C反应蛋白(hs-CRP)、甲状旁腺激素(iPTH)及IL-31、NT-4水平均较治疗前减低，且HP + HD组患者改善情况优于HD组(P &lt; 0.05)。两组治疗后BDNF水平均较治疗前增加，但差异无统计学意义(P &gt; 0.05)。结论：HP + HD治疗可通过减少部分瘙痒相关因子，从而缓解患者的皮肤瘙痒情况，且效果明显优于单纯HD治疗。</p></sec><sec id="s2"><title>关键词</title><p>尿毒症，皮肤瘙痒，血液灌流，血液透析，IL-31，NT-4，BDNF</p></sec><sec id="s3"><title>Study on the Clinical Mechanism of Hemoperfusion Combined with Hemodialysis to Improve Skin Itching in Patients with Uremia</title><p>Xiurong Xie<sup>1*</sup>, Wenxuan Ji<sup>2</sup>, Qian An<sup>2</sup>, Wenhong Shan<sup>2</sup>, Fenfen Yu<sup>2</sup>, Junyan Huang<sup>2#</sup></p><p><sup>1</sup>Department of Medicine, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Nephrology, The Second Clinical Medical College, Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/7-1571736x5_hanspub.png" /></p><p>Received: Nov. 15<sup>th</sup>, 2020; accepted: Dec. 7<sup>th</sup>, 2020; published: Dec. 14<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/7-1571736x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the effect of hemoperfusion (HP) combined with hemodialysis (HD) on the improvement of skin itching and the levels of serum interleukin-31 (IL-31), neurotrophin-4 (NT-4) and brain-derived neurotrophic factor (BDNF) in maintenance hemodialysis (MHD) patients. Methods: 64 patients who underwent maintenance hemodialysis in Qingdao Central Hospital from July 2019 to June 2020 and suffered from skin pruritus were divided into HD group and HP + HD group. The changes of skin pruritus, blood biochemical indexes and the levels of IL-31, NT-4 and BDNF before and after treatment were compared between the two groups. Results: The skin pruritus, b2-microglobulin (b2-MG), hypersensitive C-reactive protein (hs-CRP) and parathyroid hormone (iPTH), IL-31, NT-4 in the two groups after treatment were lower than before treatment. The improvement of HP + HD group was better than that of HD group (P &lt; 0.05). The levels of BDNF after treatment increased compared with before treatment in two groups, but the difference before and after was not statistically significant (P &gt; 0.05). Conclusion: The treatment of HP + HD can relieve patients’ skin pruritus by reducing some itch-related factors, and the effect is significantly better than that of HD.</p><p>Keywords:Uremia, Skin Itching, Hemoperfusion, Hemodialysis, IL-31, NT-4, BDNF</p><disp-formula id="hanspub.39123-formula19"><graphic xlink:href="//html.hanspub.org/file/7-1571736x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/7-1571736x8_hanspub.png" /> <img src="//html.hanspub.org/file/7-1571736x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>皮肤瘙痒是终末期慢性肾病(chronic kidney disease, CKD)以及维持性血液透析患者较为常见的临床症状。流行病学表明，大约49%的终末期肾病患者会出现皮肤瘙痒，且多见于男性 [<xref ref-type="bibr" rid="hanspub.39123-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39123-ref2">2</xref>]。尿毒症瘙痒对患者生活质量及生存期有明显影响，可导致生活质量下降、睡眠障碍、抑郁、焦虑，且与死亡率增加密切相关，是死亡的独立危险因子 [<xref ref-type="bibr" rid="hanspub.39123-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39123-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.39123-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.39123-ref5">5</xref>]。尿毒症瘙痒的发病机制尚不明确，有报道表明多种因子可能与其发生发展有密切关系 [<xref ref-type="bibr" rid="hanspub.39123-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.39123-ref7">7</xref>]。维持性血液透析(maintenance hemodialysis, MHD)患者可出现多种并发症，包括继发性甲状旁腺功能亢进、肾性骨营养不良、透析相关性淀粉样变及不安腿综合征等。有研究证明，MHD患者行HP + HD治疗后，其皮肤瘙痒、不安腿综合征等并发症的发病程度及发生频率均明显降低 [<xref ref-type="bibr" rid="hanspub.39123-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.39123-ref9">9</xref>]。目前关于HP + HD清除瘙痒相关因子以改善患者皮肤瘙痒的研究较少，本文旨在通过观察HP + HD治疗对尿毒症患者皮肤瘙痒的临床疗效，检测血清IL-31、NT-4、BDNF的清除情况，以探讨HP + HD改善尿毒症患者皮肤瘙痒的临床机制。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 临床资料</title><p>经医院伦理委员会批准后，选取2019年7月~2020年6月在青岛市中心医院血液净化中心行维持性血液透析且患有皮肤瘙痒的患者64例。其中，原发病构成为：糖尿病肾病22例，高血压肾病15例，慢性肾小球肾炎9例，多囊肾6例，肾病综合征1例，狼疮性肾炎1例，其他疾病10例。据透析方式不同分为HD组与HP + HD组，HD组给予常规血液透析治疗，HP + HD组给予血液灌流联合血液透析治疗。在HD组中，男19例，女13例；年龄33~70岁，平均年龄(55.56 &#177; 11.39)岁；病程20~156月，平均病程(68.28 &#177; 35.18)月。在HP + HD组中，男24例，女8例；年龄26~70岁，平均年龄(52.94 &#177; 10.95)岁；病程12~234月，平均病程(66.63 &#177; 46.34)月(表1)。入选标准：① 年龄：20~70岁；② 有明显瘙痒症状，且瘙痒超过三个月；③ 符合慢性肾脏病5D期，正在规律行维持性血液透析治疗(3次/周，每次4 h)；④本实验已获得青岛市中心医院伦理委员会批准。排除标准：① 皮肤病或血液病所导致的皮肤瘙痒；② 活动性感染；③ 精神疾病或存在其他沟通问题；④ 胆汁淤积性肝病或急性肝炎；⑤ 恶性肿瘤；⑥ 血液净化不满3个月；⑦ 不满20周岁。在年龄、性别、透析时间、原发病构成等基线资料方面，两组患者差异无统计学意义(P &gt; 0.05)，具有可比性。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General information of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >HD组</th><th align="center" valign="middle" >HP + HD组</th></tr></thead><tr><td align="center" valign="middle" >病人(例)</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >32</td></tr><tr><td align="center" valign="middle" >性别(男:女)</td><td align="center" valign="middle" >19 (59%):13 (41%)</td><td align="center" valign="middle" >24 (75%):8 (25%)</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >55.56 &#177; 11.39</td><td align="center" valign="middle" >52.94 &#177; 10.95</td></tr><tr><td align="center" valign="middle" >透析时间(月)</td><td align="center" valign="middle" >68.28 &#177; 35.18</td><td align="center" valign="middle" >66.63 &#177; 46.34</td></tr><tr><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >9 (28%)</td><td align="center" valign="middle" >13 (41%)</td></tr><tr><td align="center" valign="middle" >高血压</td><td align="center" valign="middle" >6 (19%)</td><td align="center" valign="middle" >9 (28%)</td></tr><tr><td align="center" valign="middle" >慢性肾小球肾炎</td><td align="center" valign="middle" >5 (16%)</td><td align="center" valign="middle" >4 (12%)</td></tr><tr><td align="center" valign="middle" >多囊肾</td><td align="center" valign="middle" >4 (12%)</td><td align="center" valign="middle" >2 (6%)</td></tr><tr><td align="center" valign="middle" >肾病综合征</td><td align="center" valign="middle" >1 (3%)</td><td align="center" valign="middle" >0 (0%)</td></tr><tr><td align="center" valign="middle" >狼疮性肾炎</td><td align="center" valign="middle" >1 (3%)</td><td align="center" valign="middle" >0 (0%)</td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >6 (19%)</td><td align="center" valign="middle" >4 (13%)</td></tr></tbody></table></table-wrap><p>表1. 患者的一般资料</p><p>注：表中数据以均数&#177;标准差( x &#175; &#177; s)或数字(百分比)表示。</p></sec><sec id="s6_2"><title>2.2. 实验方法</title><sec id="s6_2_1"><title>2.2.1. 材料选择</title><p>HP组：透析器，由威高集团有限公司生产，型号为HF15聚砜膜空心纤维透析器。HP + HD组：透析器，由威高集团有限公司生产，型号为F15聚砜膜空心纤维透析器；灌流器，由珠海健帆生物科技股份有限公司生产，型号为HA130血液灌流器。两组所使用血透机均为威高集团DBB-27C、德国费森尤斯4008-S或4008B，透析液均为碳酸氢盐透析液，血流量180~240 ml/min，透析液流速500 ml/min。</p></sec><sec id="s6_2_2"><title>2.2.2. 具体方法</title><p>治疗前于患者血管通路(中心静脉导管、动静脉内瘘)动脉端采血3 ml，根据视觉模拟评分法(visual analogue scale, VAS)对患者瘙痒情况进行评分。HD组给予常规血液透析治疗，治疗时间4小时；HP + HD组给予血液灌流联合血液透析治疗，治疗方法：在透析器前串联灌流器，先行HP + HD治疗2小时，取下灌流器后继续血液透析2小时。治疗结束后，再次对瘙痒情况进行评分，并于患者血管通路(中心静脉导管、动静脉内瘘)动脉端采血3 ml。血液标本经离心后留取上层血清，−80℃保存待测。待血液标本收集完成后，酶联免疫吸附测定法(ELISA)测定血清IL-31、NT-4、BDNF的水平，其他实验室数据均由医院中心实验室使用自动分析仪测定。</p></sec></sec><sec id="s6_3"><title>2.3. 观察指标及判定标准</title><p>对比两组患者治疗前后血生化指标(血尿素氮、肌酐、尿酸、血钙、血磷)、b2-MG、hs-CRP、iPTH、IL-31、NT-4及BDNF的变化情况。同时采用VAS对患者治疗前后皮肤瘙痒情况进行评分，即运用一条刻度范围为0~10 cm的标尺，以从0到10的数字大小来表示瘙痒程度(0 = 无瘙痒，10 = 难以忍受的瘙痒) [<xref ref-type="bibr" rid="hanspub.39123-ref10">10</xref>]。患者根据自身皮肤瘙痒的实际情况，在标尺上指出相应刻度，由研究者进行记录。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS 19.0统计学软件进行统计分析，计量资料以 x &#175; &#177; s统计，比较采用两独立样本t检验。计数资料以例数和百分数表示，比较采用χ<sup>2</sup>检验。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组患者治疗前后皮肤瘙痒程度改善情况</title><p>两组患者治疗后皮肤瘙痒评分均较治疗前降低，HD组治疗后较治疗前，差异无统计学意义(P &gt; 0.05)，HP + HD组治疗后较治疗前，差异有显著统计学意义(P &lt; 0.01)；HP + HD组患者治疗后皮肤瘙痒评分明显低于HD组，差异有显著统计学意义(P &lt; 0.01) (见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Improvement of skin pruritus before and after treatment in the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后</th></tr></thead><tr><td align="center" valign="middle" >HD组</td><td align="center" valign="middle" >n = 32</td><td align="center" valign="middle" >7.66 &#177; 1.29</td><td align="center" valign="middle" >7.16 &#177; 1.02</td></tr><tr><td align="center" valign="middle" >HP + HD组</td><td align="center" valign="middle" >n = 32</td><td align="center" valign="middle" >7.94 &#177; 1.27</td><td align="center" valign="middle" >4.56 &#177; 1.41<sup>ab</sup></td></tr></tbody></table></table-wrap><p>表2. 两组患者治疗前后皮肤瘙痒程度改善情况( x &#175; &#177; s)</p><p>注：a：与HD组治疗后相比，t = 8.42，P &lt; 0.01；b：与同组治疗前相比，t = 10.06，P &lt; 0.01。</p></sec><sec id="s7_2"><title>3.2. 两组患者治疗前后血生化指标的变化情况</title><p>两组患者治疗后血尿素氮、肌酐、尿酸、血磷水平均明显低于治疗前，差异有显著统计学意义(P &lt; 0.01)；HP + HD组患者治疗后血尿素氮、肌酐、尿酸、血磷水平均低于HD组，但差异无统计学意义(P &gt; 0.05)。两组患者治疗后血钙水平均稍高于治疗前，但差异无统计学意义(P &gt; 0.05) (见表3)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Changes of blood biochemical indexes before and after treatment in the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >血尿素氮(mmol/L)</th><th align="center" valign="middle" >肌酐(μmol/L)</th><th align="center" valign="middle" >尿酸(μmol/L)</th><th align="center" valign="middle" >血钙(mmol/L)</th><th align="center" valign="middle" >血磷(mmol/L)</th></tr></thead><tr><td align="center" valign="middle" >HD组</td><td align="center" valign="middle" >n = 32</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >36.72 &#177; 3.49</td><td align="center" valign="middle" >1105.72 &#177; 322.85</td><td align="center" valign="middle" >495.06 &#177; 127.24</td><td align="center" valign="middle" >2.36 &#177; 0.20</td><td align="center" valign="middle" >2.22 &#177; 0.64</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >15.53 &#177; 6.29<sup>a</sup></td><td align="center" valign="middle" >465.09 &#177; 161.26<sup>a</sup></td><td align="center" valign="middle" >153.81 &#177; 58.74<sup>a</sup></td><td align="center" valign="middle" >2.43 &#177; 0.19</td><td align="center" valign="middle" >1.23 &#177; 0.40<sup>a</sup></td></tr><tr><td align="center" valign="middle" >HP + HD组</td><td align="center" valign="middle" >n = 32</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >36.29 &#177; 4.14</td><td align="center" valign="middle" >1097.38 &#177; 276.78</td><td align="center" valign="middle" >477.00 &#177; 95.16</td><td align="center" valign="middle" >2.35 &#177; 0.17</td><td align="center" valign="middle" >2.39 &#177; 0.57</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >14.07 &#177; 5.69<sup>a</sup></td><td align="center" valign="middle" >431.63 &#177; 122.38<sup>a</sup></td><td align="center" valign="middle" >151.56 &#177; 36.54<sup>a</sup></td><td align="center" valign="middle" >2.40 &#177; 0.22</td><td align="center" valign="middle" >1.19 &#177; 0.28<sup>a</sup></td></tr></tbody></table></table-wrap><p>表3. 两组患者治疗前后血生化指标的变化情况</p><p>注：a：与同组治疗前相比，t = 7.44~18.06，P &lt; 0.01。</p></sec><sec id="s7_3"><title>3.3. 两组患者治疗前后b2-MG、hs-CRP、iPTH的变化情况</title><p>两组患者治疗后b2-MG、hs-CRP、iPTH水平均低于治疗前，HD组治疗后较治疗前，差异无统计学意义(P &gt; 0.05)，HP + HD组治疗后较治疗前，差异有统计学意义(p &lt; 0.05)；HP + HD组患者治疗后b2-MG、hs-CRP、iPTH水平均低于HD组，差异有统计学意义(p &lt; 0.05) (见表4)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Changes of b2-MG, hs-CRP, iPTH before and after treatment in the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >b2-MG</th><th align="center" valign="middle" >hs-CRP</th><th align="center" valign="middle" >iPTH</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >HD组</td><td align="center" valign="middle"  rowspan="2"  >n = 32</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >30.12 &#177; 5.77</td><td align="center" valign="middle" >12.75 &#177; 3.78</td><td align="center" valign="middle" >409.99 &#177; 394.29</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >27.74 &#177; 5.82</td><td align="center" valign="middle" >11.38 &#177; 5.15</td><td align="center" valign="middle" >343.03 &#177; 198.72</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >HP + HD组</td><td align="center" valign="middle"  rowspan="2"  >n = 32</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >31.45 &#177; 5.35</td><td align="center" valign="middle" >13.16 &#177; 18.16</td><td align="center" valign="middle" >550.24 &#177; 208.81</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >15.56 &#177; 5.71<sup>ab</sup></td><td align="center" valign="middle" >5.75 &#177; 3.07<sup>ab</sup></td><td align="center" valign="middle" >210.27 &#177; 169.59<sup>ab</sup></td></tr></tbody></table></table-wrap><p>表4. 两组患者治疗前后b2-MG、hs-CRP、iPTH的变化情况</p><p>注：a：与HD组治疗后相比，t = 2.88~8.45，P &lt; 0.05；b：与同组治疗前相比，t = 2.28~11.49，P &lt; 0.05。</p></sec><sec id="s7_4"><title>3.4. 两组患者治疗前后IL-31、NT-4、BDNF的变化情况</title><p>两组患者治疗后IL-31、NT-4水平均低于治疗前，HD组治疗后较治疗前，差异无统计学意义(P &gt; 0.05)，HP + HD组治疗后较治疗前，差异有显著统计学意义(P &lt; 0.01)；HP + HD组患者治疗后IL-31、NT-4水平明显低于HD组，差异有显著统计学意义(P &lt; 0.01)；两组患者治疗后BDNF水平均高于治疗前，但差异无统计学意义(P &gt; 0.05) (见表5)。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Changes of IL-31, NT-4, BDNF before and after treatment in the two groups (pg/ml</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >IL-31</th><th align="center" valign="middle" >NT-4</th><th align="center" valign="middle" >BDNF</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >HD组</td><td align="center" valign="middle"  rowspan="2"  >n = 32</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >792.87 &#177; 296.61</td><td align="center" valign="middle" >25.82 &#177; 10.86</td><td align="center" valign="middle" >47.94 &#177; 2.67</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >671.10 &#177; 178.29</td><td align="center" valign="middle" >22.01 &#177; 4.01</td><td align="center" valign="middle" >48.03 &#177; 2.95</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >HP + HD组</td><td align="center" valign="middle"  rowspan="2"  >n = 32</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >800.37 &#177; 295.60</td><td align="center" valign="middle" >24.98 &#177; 10.06</td><td align="center" valign="middle" >48.09 &#177; 2.67</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >468.23 &#177; 145.05<sup>ab</sup></td><td align="center" valign="middle" >15.01 &#177; 4.01<sup>ab</sup></td><td align="center" valign="middle" >48.55 &#177; 2.95</td></tr></tbody></table></table-wrap><p>表5. 两组患者治疗前后IL-31、NT-4、BDNF的变化情况(pg/ml)</p><p>注：a：与HD组治疗后相比，t = 4.99~6.99，P &lt; 0.01；b：与同组治疗前相比，t = 5.21~5.71，P &lt; 0.01。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>尿毒症患者皮肤瘙痒的临床表现存在个体差异。Sanzida S. Swarna等人发现，绝大部分患者几乎每天都会出现瘙痒症状，其瘙痒呈双侧分布，具有范围广、不连续及对称分布的特征 [<xref ref-type="bibr" rid="hanspub.39123-ref11">11</xref>]。A. Wieczorek等人还发现，皮肤瘙痒的发病部位、持续时间及发病频率均可出现不同，常见部位为背部，其次为臀部、腹部和腰骶部 [<xref ref-type="bibr" rid="hanspub.39123-ref12">12</xref>]。通常患者的瘙痒情况，夏季发病频率和程度均高于冬季，且夜间高于白天 [<xref ref-type="bibr" rid="hanspub.39123-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.39123-ref14">14</xref>]。瘙痒的强度和分布部位也会随病程的延长有所不同 [<xref ref-type="bibr" rid="hanspub.39123-ref11">11</xref>]，且瘙痒强度与病程呈正相关 [<xref ref-type="bibr" rid="hanspub.39123-ref1">1</xref>]。</p><p>尿毒症瘙痒的发病机制目前尚不清楚，多项研究表明尿毒症瘙痒不是单一因素所致，而是多种因素通过不同的作用机制共同作用于机体所产生。导致皮肤瘙痒的可能原因有 [<xref ref-type="bibr" rid="hanspub.39123-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.39123-ref16">16</xref>]：① 皮肤干燥状态。患者在接受血液透析过程中，皮肤的角质层随病程延长而发生病理性改变，从而导致皮肤功能出现异常。② 血浆中组胺水平升高。组胺及其代谢产物主要经肾脏排泄，当肾脏功能出现异常时，组胺会在皮肤及胃肠黏膜中囤积。③ 皮肤中钙离子、磷酸根离子和镁离子等二价离子浓度升高。④ 继发性甲状旁腺功能亢进及iPTH水平升高。有文献报道称，行甲状旁腺切除术后，大部分维持性血液透析且伴有皮肤瘙痒的患者表示，其瘙痒情况较前明显减轻 [<xref ref-type="bibr" rid="hanspub.39123-ref17">17</xref>]。在本研究中，经HP + HD治疗后，iPTH明显下降亦证实iPTH的升高与尿毒症皮肤瘙痒相关。⑤ 免疫炎症学说。有研究称，MHD患者血清检测示多种炎性标志物(如血清C反应蛋白、白介素-6 (IL-6)、辅助T淋巴细胞等)含量增加，且瘙痒患者高于无瘙痒患者，提示瘙痒患者体内存在炎症状态 [<xref ref-type="bibr" rid="hanspub.39123-ref18">18</xref>]。在本研究中，经HP + HD治疗后，IL-31、NT-4明显下降提示IL-31、NT-4升高与尿毒症皮肤瘙痒相关。⑥ 血液中阿片样受体物质增加。⑦ 周围神经病变。</p><p>IL-31属于白介素家族，主要由活化的辅助型T细胞2产生，以二聚体复合物的形式发挥生物学作用。其复合物由IL-31受体A和抑瘤素M受体b与IL-31共同形成。NT-4与BDNF均属于神经营养因子家族，二者具有相似的结构及生物学活性。NT-4可与受体酪氨酸激酶A及神经营养素受体p75相结合，BDNF可与受体酪氨酸激酶B及神经营养素受体p75相结合，两者对受体的亲和力不同，从而对感觉、运动中枢的功能产生多种影响。Rodney D Britt等人发现，当转基因小鼠出现严重瘙痒及脱毛现象时，小鼠血清IL-31水平明显升高；气道过敏性动物模型显示，IL-31受体及BDNF受体在病变组织较正常组织中表达增加，这表明IL-31和BDNF可能参与了过敏性和非过敏性疾病的皮炎发生 [<xref ref-type="bibr" rid="hanspub.39123-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.39123-ref20">20</xref>]。Bernhard F Gibbs等人发现，特应性皮炎患者血清IL-31、NT-4及BDNF水平高于正常对照组，且证实IL-31、NT-4与皮肤瘙痒严重程度呈显著正相关 [<xref ref-type="bibr" rid="hanspub.39123-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.39123-ref21">21</xref>]，这表明IL-31、NT-4及BDNF可能参与了特应性皮炎的发生发展，并在其过程中起关键作用。柯美菊等人发现，在伴有瘙痒症状的MHD患者中，血清IL-31水平较无瘙痒患者显著升高，且与瘙痒强度呈正相关 [<xref ref-type="bibr" rid="hanspub.39123-ref6">6</xref>]。Neveen E Sorour等人发现尿毒症瘙痒患者血清NT-4水平升高，且与瘙痒严重程度有显著相关性；尿毒症瘙痒患者血清BDNF水平高于无瘙痒患者，但差异无统计学意义，推测BDNF本身的升高可能促进了其他在瘙痒中真正起作用的因素发挥功能 [<xref ref-type="bibr" rid="hanspub.39123-ref7">7</xref>]。综上所述，IL-31、NT-4及BDNF可能参与了尿毒症瘙痒的发生发展，可能是该过程中的重要瘙痒相关因子，清除该类因子可改善患者的皮肤瘙痒症状。</p><p>在本研究中，经HP + HD治疗后，患者的皮肤瘙痒情况得到改善，患者血IL-31及NT-4水平亦降低，推测IL-31、NT-4可能与尿毒症患者皮肤瘙痒有一定相关性。但本研究中未出现BDNF的明显变化，这与Neveen E Sorour等人的发现相一致，推测BDNF本身并不直接参与皮肤瘙痒的发生发展，仅协同其他因子发挥致痒作用，这仍需进一步完善相关实验进行验证。</p><p>常规HD治疗主要是通过弥散和对流原理来清除小分子水溶性物质(如尿素氮、肌酐等)和过多的水分；而对中、大分子物质(如b2-MG、iPTH、白介素等)均无法清除或仅能部分清除。随着病程延长，必然导致MHD患者体内蓄积大量无法完全清除的毒素。HP治疗是通过灌流器中的吸附剂与体内待清除的物质相结合，达到清除这些物质的目的。HP + HD兼具HP和HD的吸附和清除性能，对多种物质均具有较好的清除能力。本实验结果显示，两组患者治疗后皮肤瘙痒情况均较治疗前减轻，且HP + HD组较HD组缓解程度更明显；在清除小分子毒素方面，两组间无差别，但在清除iPTH、b2-MG、hs-CRP及IL-31、NT-4等中、大分子方面，HP + HD组清除效果显著优于HD组。这充分显示了HP + HD在缓解患者皮肤瘙痒方面的积极作用以及清除中、大分子方面的优势。现已有多个报道肯定了血液灌流联合血液透析在改善患者皮肤瘙痒方面的有效性 [<xref ref-type="bibr" rid="hanspub.39123-ref9">9</xref>]，本研究结果与之相符。</p><p>本研究提示，单次HP + HD治疗可通过清除尿毒症患者血清IL-31、NT-4、iPTH、b2-MG、hs-CRP改善患者皮肤瘙痒情况，且效果优于单纯血液透析治疗。目前，血液灌流器本身价格昂贵，且部分地区未将其纳入医保或医保报销比例较小。因本研究提示单次HP + HD治疗也可缓解患者的皮肤瘙痒情况，所以必要时，部分患者可通过长间隔的单次HP + HD治疗来间断改善自身的瘙痒情况。但仍建议患者在经济条件允许的情况下，积极实行长程血液灌流联合血液透析治疗，以系统的改善患者皮肤瘙痒情况，清除体内毒素，缓解临床症状，从而提高生活质量。</p><p>本研究尚存在以下局限性：① 样本含量过小。② 与任何横断面研究一样，不能确定各因素与尿毒症瘙痒之间的因果关系和时间性。③ 本研究中不包括腹膜透析患者。后续会通过增加样本含量，完善相关研究，从而对血液透析及腹膜透析患者的尿毒症瘙痒与各因素之间的因果关系作进一步阐述。</p></sec><sec id="s9"><title>文章引用</title><p>解秀荣,季文萱,安 茜,单文红,于芬芬,黄俊彦. 血液灌流联合血液透析改善尿毒症患者皮肤瘙痒的临床机制研究Study on the Clinical Mechanism of Hemoperfusion Combined with Hemodialysis to Improve Skin Itching in Patients with Uremia[J]. 临床医学进展, 2020, 10(12): 2890-2897. https://doi.org/10.12677/ACM.2020.1012437</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39123-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Satti, M.Z., Arshad, D., Javed, H., et al. (2019) Uremic Pruritus: Prevalence and Impact on Quality of Life and Depressive Symptoms in Hemodialysis Patients. Cureus, 11, e5178. &lt;br&gt;https://doi.org/10.7759/cureus.5178</mixed-citation></ref><ref id="hanspub.39123-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rayner, H.C., Larkina, M., Wang, M., et al. (2017) International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis. Clinical Journal of the American Society of Nephrology, 12, 2000-2007.  
&lt;br&gt;https://doi.org/10.2215/CJN.03280317</mixed-citation></ref><ref id="hanspub.39123-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ting, S.-W., Fan, P.-C., Lin, Y.-S., et al. (2020) Association between Uremic Pruritus and Long-Term Outcomes in Patients Undergoing Dialysis. Journal of the American Academy of Dermatology, 83, 924-925.  
&lt;br&gt;https://doi.org/10.1016/j.jaad.2020.01.011</mixed-citation></ref><ref id="hanspub.39123-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Suseł, J., Batycka-Baran, A., Reich, A. and Szepietowski, J.C. (2014) Uraemic Pruritus Markedly Affects the Quality of Life and Depressive Symptoms in Haemodialysis Patients with End-Stage Renal Disease. Acta Dermato-Venereologica, 94, 276-281. &lt;br&gt;https://doi.org/10.2340/00015555-1749</mixed-citation></ref><ref id="hanspub.39123-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ibrahim, M.K., Elshahid, A.R., El Baz, T.Z., et al. (2016) Impact of Uraemic Pruritus on Quality of Life among End Stage Renal Disease Patients on Dialysis. Journal of Clinical and Diagnostic Research, 10, WC01-WC05.  
&lt;br&gt;https://doi.org/10.7860/JCDR/2016/16273.7488</mixed-citation></ref><ref id="hanspub.39123-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ko, M.-J., Peng, Y.-S., Chen, H.-Y., et al. (2014) Interleukin-31 Is Associated with Uremic Pruritus in Patients Receiving Hemodialysis. Journal of the American Academy of Dermatology, 71, 1151-1159.E1.  
&lt;br&gt;https://doi.org/10.1016/j.jaad.2014.08.004</mixed-citation></ref><ref id="hanspub.39123-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sorour, N.E., Elesawy, F.M., Tabl, H.A., Ibrahim, M.E. and Akl, E.M. (2019) Evaluation of Serum Levels of Neurotrophin 4 and Brain-Derived Nerve Growth Factor in Uremic Pruritus Patients. Clinical, Cosmetic and Investigational Dermatology, 12, 109-114. &lt;br&gt;https://doi.org/10.2147/CCID.S190917</mixed-citation></ref><ref id="hanspub.39123-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Cai, W., et al. (2015) Efficacy and Mechanism of Hemoperfusion plus Hemodialysis for Peripheral Neuropathy of Uremic Patients on Maintenance Hemodialysis. Zhonghua Yi Xue Za Zhi, 95, 1319-1322.</mixed-citation></ref><ref id="hanspub.39123-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cupisti, A., Piccoli, G.B. and Gallieni, M. (2020) Charcoal for the Management of Pruritus and Uremic Toxins in Patients with Chronic Kidney Disease. Current Opinion in Nephrology and Hypertension, 29, 71-79.  
&lt;br&gt;https://doi.org/10.1097/MNH.0000000000000567</mixed-citation></ref><ref id="hanspub.39123-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Furue, M., Ebata, T., Ikoma, A., et al. (2013) Verbalizing Extremes of the Visual Analogue Scale for Pruritus: A Consensus Statement. Acta Dermato-Venereologica, 93, 214-215. &lt;br&gt;https://doi.org/10.2340/00015555-1446</mixed-citation></ref><ref id="hanspub.39123-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Swarna, S.S., Aziz, K., Zubair, T., et al. (2019) Pruritus Associated With Chronic Kidney Disease: A Comprehensive Literature Review. Cureus, 11, e5256. &lt;br&gt;https://doi.org/10.7759/cureus.5256</mixed-citation></ref><ref id="hanspub.39123-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wieczorek, A., Krajewski, P., Kozioł-Gałczyńska, M. and Szepietowski, J.C. (2020) Opioid Receptors Expression in the Skin of Haemodialysis Patients Suffering from Uraemic Pruritus. Journal of the European Academy of Dermatology and Venereology, 34, 2368-2372. &lt;br&gt;https://doi.org/10.1111/jdv.16360</mixed-citation></ref><ref id="hanspub.39123-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Verduzco, H.A. and Shirazian, S. (2020) CKD-Associated Pruritus: New Insights into Diagnosis, Pathogenesis, and Management. Kidney International Reports, 5, 1387-1402. &lt;br&gt;https://doi.org/10.1016/j.ekir.2020.04.027</mixed-citation></ref><ref id="hanspub.39123-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">陈敢, 王丽妍, 傅君舟, 刘文虎, 吴雯婷, 谢志强. 维持性血液透析患者中瘙痒症的现状调查研究[J]. 中国血液净化, 2019, 18(4): 242-245.</mixed-citation></ref><ref id="hanspub.39123-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Reszke, R. and Szepietowski, J.C. (2018) End-Stage Renal Disease Chronic Itch and Its Management. Dermatologic Clinics, 36, 277-292. &lt;br&gt;https://doi.org/10.1016/j.det.2018.02.007</mixed-citation></ref><ref id="hanspub.39123-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Attia, E.A. and Hassan, A.A. (2014) Uremic Pruritus Pathogenesis, Revisited. Arab Journal of Nephrology and Transplantation, 7, 91-96.</mixed-citation></ref><ref id="hanspub.39123-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">于婵媛, 杨立志, 窦海川, 张洋, 王月红. 不同外科术式治疗尿毒症继发性甲状旁腺功能亢进的效果分析[J]. 中国血液净化, 2017, 16(1): 44-47.</mixed-citation></ref><ref id="hanspub.39123-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kremer, A.E. and Mettang, T. (2019) Pruritus in Systemic Diseases: Common and Rare Etiologies. Der Internist, 60, 814-820. &lt;br&gt;https://doi.org/10.1007/s00108-019-0637-0</mixed-citation></ref><ref id="hanspub.39123-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Britt Jr., R.D., Thompson, M.A., Wicher, S.A., et al. (2019) Smooth Muscle Brain-Derived Neurotrophic Factor Contributes to Airway Hyperreactivity in a Mouse Model of Allergic Asthma. FASEB Journal, 33, 3024-3034.  
&lt;br&gt;https://doi.org/10.1096/fj.201801002R</mixed-citation></ref><ref id="hanspub.39123-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Güvercin, B., et al. (2019) The Relationship between Dermatological Findings and Serum Interleukin 31 and Serum Uridine Diphosphate Glucose Ceramide Glucosyltransferase Levels among Patients with Chronic Kidney Disease. Hippokratia, 23, 75-80.</mixed-citation></ref><ref id="hanspub.39123-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Gibbs, B.F., Patsinakidis, N. and Raap, U. (2019) Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases. Frontiers in Immunology, 10, 1383. &lt;br&gt;https://doi.org/10.3389/fimmu.2019.01383</mixed-citation></ref></ref-list></back></article>